Microsaic Systems
Microsaic Systems Showcases Miniaturized Mass Spectrometry at PITTCON 2014: Microsaic Systems, a high technology company developing, marketing and manufacturing next generation mass spectrometry (MS) instruments, is showcasing its latest innovative products offering enhanced productivity and time and cost savings… Read More
Omega Diagnostics
CD4 Update – Successful completion of Technology Transfer – Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the successful completion of its CD4 technology transfer project with first in-field evaluations to… Read More
Microsaic Systems
Microsaic Systems is pleased to announce the launch of the MiDas™ interface module which allows simple connectivity of its miniaturised mass detector, the 4000 MiD®, for on line and off line analysis. The MiDas compact integrated interface unit offers automated sampling,… Read More
Omega Diagnostics
positive CD4 batch results
DefiniGEN
Parkwalk closes DefiniGEN investment for the University of Cambridge Enterprise Fund II DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology. The Company provides human cells… Read More
Omega Diagnostics
Omega Diagnostics: ‘majority’ of CD4 manufacturing variants eliminated
Oxyntix
Parkwalk closes follow-on investment in Oxyntix. Oxyntix is developing and commercialising new technologies in energy and process engineering. The technology has numerous applications, notably in nuclear fusion power generation and in sonochemistry, among others, by developing a new… Read More
Microsaic Systems
Interim results: Revenues up 100%: Microsaic Systems plc (AIM: MSYS), the developer of chip-based scientific instruments, announces its interim results for the six months ended 30 June 2013 and an update on trading since the period end. Highlights… Read More
Omega Diagnostics
Parkwalk closes Omega Diagnostic plc investment Omega Diagnostics is focused on selling a wide range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within three segments: Allergy and Autoimmune, Food Intolerance and Infectious Disease. The… Read More
Eykona
Times: 3-D camera brings health service’s link to innovators into sharp focus
Microsaic Systems
Parkwalk closes investment in Microsaic Systems plc for the UK Tech Fund IV & ZeroND Fund Microsaic is the first, and only company to have successfully miniaturised mass spectrometry through the development of its patented chip-based technologies. These… Read More
DefiniGEN
Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund I DefiniGEN provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes. The Company’s proprietary production platform OptiDIFF robustly generates human… Read More
Eykona
BIS highlights Eykona in report
